GT Biopharma Inc (GTBP)

GT Biopharma's stock price has experienced significant volatility, with a substantial decrease over the last year, but some short-term increases recently. Key events impacting the stock price include the advancement of clinical trials, warrant exercises, earnings reports, and stock offerings. Progress in clinical trials, such as advancing GTB-3650 into Cohort 3 of its Phase 1 trial, has positively influenced investor sentiment. The company has released quarterly financial results, including a Q3 net loss of $3.1 million. GT Biopharma has also filed to sell shares of common stock for holders and registered shares for resale by selling stockholders.

Traditional demand seasonality is not directly applicable to GT Biopharma's products and services. The demand for its therapeutic products is primarily driven by the progress and success of its clinical trials, regulatory approvals, and the treatment needs of the diseases it targets. The company's financial performance and perceived value are more closely tied to research and development milestones, clinical data, and potential market access rather than seasonal consumer purchasing patterns.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapeutic products, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparations industry. The company's core business revolves around its Tri-specific Killer Engager (TriKE®) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms, designed to enhance the cancer-killing abilities of a patient's natural killer (NK) cells. Major products and product candidates include GTB-3550 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), GTB-3650 targeting CD33 on myeloid leukemias, GTB-5550 targeting B7-H3 on advanced solid tumors, GTB-7550 for lupus and other autoimmune disorders, and other product candidates like GTB-6550 and GTB-1050.

GT Biopharma, Inc. is headquartered in San Francisco, California, and operates in the United States. The company holds a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using its TriKE technology.

GT Biopharma's brand reputation appears moderately positive, with some analysts rating the stock as "Moderate Buy" or "Very Bullish." Advancements in clinical trials for its TriKE platform and product candidates like GTB-3650 contribute positively to its scientific and developmental reputation. However, the significant decline in stock price over the past year could negatively impact investor confidence and public perception. Online sentiment indicators show a mix of bullish and bearish views among users.

The ownership structure of GT Biopharma (GTBP) includes retail, insider, and institutional investors. Retail investors hold the largest portion, approximately 85.14% to 90.08% of the company's stock. Insiders own about 8.05% to 11.34%, while institutional shareholders hold around 1.34% to 8.15%. Major institutional owners include DRW Securities, LLC, Bank Of Montreal, Citadel Advisors Llc, Geode Capital Management, Llc, Two Sigma Securities, Llc, Morgan Stanley, Vanguard Group Inc, and Wells Fargo & Company. The largest individual shareholder is Michael Martin Breen, who owns 856,218 shares, representing 8.05% of the company.